Navigation Links
Preventing the spread of HIV/AIDS with humanized BLT mice
Date:5/18/2011

CHAPEL HILL, N.C. The more than 2.7 million new HIV infections recorded per year leave little doubt that the HIV/AIDS epidemic continues to spread globally. That's why there's the need for safe, inexpensive and effective drugs to successfully block HIV transmission.

A new study from the University of North Carolina at Chapel Hill School of Medicine further validates the use of humanized BLT mice in the fight to block HIV transmission. The "BLT" name is derived from the fact that these designer mice are created one at a time by introducing human bone marrow, liver and thymus tissues into animals without an immune system of their own. Humanized BLT mice have a fully functioning human immune system and can be infected with HIV in the same manner as humans.

The pioneering developers of the humanized BLT mouse model are Paul Denton, PhD, instructor of medicine and J. Victor Garcia-Martinez, PhD, professor of medicine in the UNC Center for Infectious Diseases and the UNC Center for AIDS Research.

In the study published online Wednesday, May 18 in the Journal of Virology, Denton and colleagues provide data that validates humanized BLT mice as a preclinical experimental system that potentially can be used to develop and test the effectiveness of experimental HIV prevention approaches and topical microbicides.

The animal study reproduced the design and methods of a recent double-blind clinical study in 889 women of the topical microbicide tenofovir. That study, the CAPRISA 004 trial, tested topical pre-exposure prophylaxis (PrEP) with 1 percent tenofovir which participants were instructed to apply vaginally twice daily. The 2.5 year trial resulted in an overall 39 percent reduction in instances of vaginal HIV transmission. Among women who self-reported as strongly adhered to the recommended instructions the protection figure climbed to 54 percent.

The new topical PrEP study by Denton and coauthors in humanized BLT mice reproduced the CAPRISA experimental design with tenofovir. The researchers say they "observed "88 percent protection of vaginal HIV-1 transmission," which was further confirmed by lack of detectable virus anywhere in the animals.

The researchers then tested six additional microbicide drug candidates for their ability to prevent vaginal HIV transmission. These experimental compounds, not yet tested in people, interfere with the virus' ability to reproduce. Partial or complete protection was shown by all but one of these drug candidates. Based on these positive results, Denton said these inhibitor drugs warrant serious consideration for future testing in people.

"This animal model has great potential value for testing and predicting the HIV preventive benefits of the second generation of microbicide candidates that are aimed at preventing viral replication," Garcia said. "The results of these studies will help provide important information for current and future clinical trials."


'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging
2. Preventing blindness focus of ORNL technology, AMDx
3. Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease
4. Surgery, Stenting Fare Equally Well in Preventing Stroke
5. Landmark Clinical Trial Shows Surgery and Stenting Equally Safe and Effective at Preventing Stroke
6. Dual Therapy Best for Preventing Bleeding After Heart Procedures
7. The Rubit Dog Tag Clips Making Big Pet Store Sales, Everyday Dog Ownership Easier, Preventing Broken Fingernails.
8. Circumcising gay men would have limited impact on preventing HIV
9. Studies offer encouraging data on preventing Crohns disease recurrence
10. UCI gets major funding to study ways of preventing drug-resistant staph infections
11. New clinical trial explores role of vitamin D in preventing esophageal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
(Date:2/12/2016)... Washington, NC (PRWEB) , ... February 12, 2016 , ... ... the surrounding areas, is initiating a charity drive that will raise funds earmarked to ... at John C. Tayloe Elementary School. , “My school is in a low-income area ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... of the Pittsburgh metro area, celebrates the beginning of the latest charity campaign ... develop social skills through art. Donations to this worthy cause are currently being ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... 2016 - Cardiac Marker ... Medicine and Cancer Therapy. - European Point of ... Markets. - Key Diagnostic Testing Markets. - ... in Genetic Testing. - Molecular Diagnostics in Infectious ... Over-the-Counter Diagnostic Products World Markets. - Point of ...
Breaking Medicine Technology: